A) | | |
CONFLICT OF INTEREST AND PRIMARY TOPIC | ALL GUIDELINES, N (%)*(N = 196) | ALL GUIDELINES EXCLUDING SUBSECTIONS,† N (%)*(N = 119) |
|
Conflict of interest statement | | |
• In guideline | 61 (31.1) | 28 (23.5) |
• Separate website | 9 (4.6) | 9 (7.6) |
• Not provided | 126 (64.3) | 82 (68.9) |
Primary topic of guideline | | |
• Public health | 42 (21.4) | 15 (12.6) |
• Infectious disease | 37 (18.9) | 8 (6.7) |
• Pediatrics | 20 (10.2) | 20 (16.8) |
• Neurology | 11 (5.6) | 5 (4.2) |
• Cardiology | 10 (5.1) | 10 (8.4) |
• Oncology | 9 (4.6) | 9 (7.6) |
• Pulmonology | 9 (4.6) | 9 (7.6) |
• Endocrinology | 8 (4.1) | 8 (6.7) |
• Obstetrics and gynecology | 8 (4.1) | 8 (6.7) |
• Psychiatry | 6 (3.1) | 6 (5.0) |
• Nonspecific | 26 (13.3) | 11 (9.2) |
• Other‡ | 10 (5.1) | 10 (8.4) |
B) | | |
TYPE OF SPONSOR | ALL GUIDELINES, N (%)* TOTAL NO. OF SPONSORS, N = 446§|| | ALL GUIDELINES EXCLUDING SUBSECTIONS, N (%) TOTAL NO. OF SPONSORS, N = 236§|| |
|
Foundation or charity | 12 (2.7) | 12 (5.1) |
Government | 147 (32.9) | 91 (38.6) |
Society or association | 77 (17.3) | 65 (27.5) |
Professional body | 14 (3.1) | 14 (5.9) |
Medical industry | 177 (39.7) | 41 (17.4) |
Other | 18 (4.0) | 12 (5.1) |
Unclear | 1 (0.2) | 1 (0.4) |